Baker Bros. Advisors LP bought $29M of KYMR
director at Kymera Therapeutics, Inc.. 655,500 shares at an average of $44.00, traded Jun 30, 2025, filed Jun 30, 2025.
Score components
- +15RoleDirector
- +25Trade size$28.8M at market
- +10Relative to holdingsHoldings up 137%
- +4Price context17% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-091829, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +55,191 | $44.00 | $2.4M | 534,134 | Jun 30, 2025 |
| Jun 30, 2025 | POpen-market purchase Common Stockindirect: See Footnotes | +600,309 | $44.00 | $26M | 6,117,295 | Jun 30, 2025 |
| Jun 30, 2025 | POpen-market purchase Prefunded Warrantsderivativeindirect: See Footnotes | +55,191 | $44.00 | $2.4M | 974,192 | Jun 30, 2025 |
| Jun 30, 2025 | POpen-market purchase Prefunded Warrantsderivativeindirect: See Footnotes | +600,309 | $44.00 | $26M | 10,225,962 | Jun 30, 2025 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 33Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $56M 513,245 shares | -18% | |
| 28Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $3.4M 31,283 shares | -1% | |
| 68Notable | Kymera Therapeutics, Inc. | Bvf Partners L P/il director, other | $174M 1,630,658 shares | -58% | |
| 33Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $44M 398,765 shares | -12% | |
| 28Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $35M 285,684 shares | -9% | |
| 33Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $45M 478,198 shares | -4073% | |
| 28Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $3.3M 31,798 shares | -1% | |
| 19Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $540k 6,000 shares | -102% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.